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Introduction
Plasma is described as the fourth fundamental state 
of the matter. There are various biomedical appli-
cations of nonthermal plasma, such as steriliza-
tion.1,2 However, its production at an atmospheric 
pressure (cold atmospheric plasma, CAP) made 
possible its use for other medical applications 
(wound healing, blood coagulation, antibacterial 
treatment, endothelial cell proliferation and more) 
and while some devices are already used clinically,3 
others are still on the benchside. Two predominant 
types of plasma discharge devices can be distin-
guished: direct or indirect discharge sources.2,4–6 
Direct plasma discharge sources [e.g. dielectric 
barrier discharge (DBD)] use the target area as a 
counter electrode. These direct plasma sources cre-
ate relatively homogenous plasmas containing high 
concentrations of plasma-generated species. 
Although the control of the plasma composition 
still remains a big challenge, these direct discharge 
sources are able to control the plasma composition 
more easily compared with other discharge devices.4 
The major disadvantage of this technique is the 
application distance (between the electrodes) which 
must remain within a close range, generally less 
than 3 mm2, thus limiting its use for small areas of 
the human body.4 Indirect discharge sources (e.g. 
plasma jet) refer to various discharge systems used 
in plasma science. Hence numerous configurations 
are found. It generally refers to a system where the 
carrier gas discharge is operated in a non-sealed 
electrode arrangement.7 Plasma jets can be classi-
fied according to parameters such as discharge 
geometry, electrode arrangement, excitation 
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Abstract
Background: Cold-atmospheric plasma (CAP) is an ionized gas produced at an atmospheric 
pressure. The aim of this systematic review is to map the use of CAP in oncology and the 
implemented methodologies (cell targets, physical parameters, direct or indirect therapies).
Methods: PubMed, the International Clinical Trials Registry Platform and Google Scholar 
were explored until 31 December 2017 for studies regarding the use of plasma treatment in 
oncology (in vitro, in vivo, clinical trials).
Results: 190 original articles were included. Plasma jets are the most-used production 
systems (72.1%). Helium alone was the most-used gas (35.8%), followed by air (26.3%) and 
argon (22.1%). Studies were mostly in vitro (94.7%) and concerned direct plasma treatments 
(84.2%). The most targeted cancer cell lines are human cell lines (87.4%), in particular, in 
brain cancer (16.3%).
Conclusions: This study highlights the multiplicity of means of production and clinical 
applications of the CAP in oncology. While some devices may be used directly at the bedside, 
others open the way for the development of new pharmaceutical products that could be 
generated at an industrial scale. However, its clinical use strongly needs the development of 
standardized reliable protocols, to determine the more efficient type of plasma for each type 
of cancer, and its combination with conventional treatments.
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frequency or pattern. More information may be 
found in the work by Winter and colleagues.7  
The concentration in reactive oxygen and nitrogen 
species (RONS) is lower than in direct 
discharge sources and the plasma generated is less 
controllable.4 However, the use of some specific 
carrier gases makes it possible to obtain changes in 
plasma composition.4
Two methods of applying plasma are also 
described: direct treatment and indirect treatment 
using plasma-activated media or solution (PAM).5 
The first method consists of applying directly the 
CAP on in vitro cells, in vivo models or human liv-
ing tissues. The second strategy consists of pro-
ducing PAM and then applying/injecting it into 
cell cultures or tumors. More information can be 
found in the work by Yan and colleagues.5
In vitro plasma-exposed eukaryotic cells demonstrate 
several effects such as cell detachment, cell migra-
tion alteration, apoptosis or necrosis according to 
cell type and exposure parameters (power, time of 
exposure).2 Similar effects have been observed with 
cancer cell lines, including apoptosis8 and decreased 
cell migration.9,10 Studies even suggest that cancer 
cells are more sensitive to CAP treatment than nor-
mal cells, concluding a selective decrease in cancer 
cell viability with less cytotoxic effect on nonmalig-
nant cells.11–15 The understanding of the mecha-
nisms responsible for this selectivity is based on 
several hypotheses that they depend on the basal 
intracellular level in reactive oxygen species (ROS), 
the expression of aquaporins, or more recently, on 
the cholesterol composition of the membrane.16,17
CAP induces both physical effects (production of 
ultraviolet rays, heat and electromagnetic fields) 
as well as chemical effects (production of RONS). 
Whereas the physical effects seem to have a negli-
gible cellular impact,18,19 RONS may induce cell 
membrane alterations, an increase in intracellular 
ROS, a decrease of the antioxidant potential and 
DNA double-strand brakes, and subsequently, 
apoptosis.5 For example, singlet oxygen resulting 
from the application of direct application of CAP 
or PAM is able to stimulate the production by 
tumor cells of secondary singlet oxygen. These 
secondary species induce a decrease in activity of 
catalase, SOD (superoxide dismutase), nicotina-
mide adenine dinucleotide phosphate oxidase or 
the first apoptosis signal receptor and secondarily, 
a greater sensitivity to RONS. Cytotoxic T cells 
may also be stimulated. More details may be 
found in the work by Bauer and colleagues.20,21
To summarize, at present, many basic cellular 
responses (apoptosis, growth inhibition, selec-
tive cancer cell death, cell cycle arrest, DNA 
and mitochondrial damage, selective increase of 
ROS, or even immunogenic cell death) have 
been demonstrated following CAP treatment.22 
Recently, Keidar and colleagues,22 taking into 
account these cellular responses, devised a self-
adaptive plasma discharge system. Some cellu-
lar responses following the treatment could be 
measured and taken into account to automati-
cally adapt some CAP parameters, such as com-
position or power, to obtain the most efficient 
treatment possible.
We are keen to provide an overview of this con-
stantly evolving and promising field of plasma 
use in oncology. The aim of this systematic 
review is to map the use of plasma in oncology 
and the different methodologies implemented so 
far (cell targets, physical parameters, direct or 
indirect therapies).
Materials and methods
This systematic review was performed in accord-
ance with the preferred reporting items for sys-
tematic reviews and meta-analyses guidelines.23
Data sources and research strategy
Two major electronic databases were searched: 
PubMed and Google Scholar. Clinical trials were 
also identified through the International Clinical 
Trials Registry Platform search portal (available 
at http://apps.who.int/trialsearch/).
The research strategy (Table S1) combines both 
keywords related to plasma (e.g. ‘plasma dis-
charge’ or ‘atmospheric plasma’) and keywords 
related to medical fields (e.g. tumor, oncology).
This strategy was then slightly adapted to meet 
requirements of each database. Reference lists of 
query studies were inspected to identify any addi-
tional relevant published or unpublished data. 
The last research was conducted on 18 January 
2018. All citations published after the 31 
December 2017 were not considered.
Inclusion criteria
All original reports regarding the use of plasma as 
a treatment therapy in oncology were included in 
this systematic review. In vitro, in vivo studies, 
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and clinical trials were considered. Language of 
publication was restricted to English.
Outcomes
The following outcomes were considered: the 
countries of authors’ affiliations (each author’s 
nationality was recorded, a study could be related 
to several countries), the type of methodology (in 
vivo, in vitro, clinical trial), the type of plasma dis-
charge device used (DBD or plasma jet), the gas 
used to produce the plasma (helium, air, argon, 
azote, with/without adjuvant), the application 
protocol (direct or indirect treatment) and when 
applicable, and type of tumor cells (type of cancer 
or origin of the tumor cell line).
Study selection and data extraction
All results were screened based on titles and 
abstracts. Full texts of the potentially selected 
records were obtained for definitive inclusion. 
Reviews and conference proceedings were not 
excluded but were considered apart. A standard-
ized extraction form was created to collect data 
according to the outcomes detailed above (Table 
S2). Data extraction was performed twice by one 
author (AD) at a 1-month interval.
Results
A total of 3731 results were identified, corresponding 
to 3697 unique citations. Based on the inclusion 
criteria described above, 3468 unique citations 
were excluded, of which there was one study in 
Chinese, one in Korean, one in German and one in 
French6,24–26 A final total of 229 results were included: 
190 original articles (82.9%), 30 reviews (13.1%), 7 
conference proceedings and 2 ongoing clinical trials. 
A flow diagram is available (Figure S1). Details for 
each study are presented in Table S2.
From 2005, the number of original articles has 
grown exponentially [Figure 1(a)] while the pro-
portion of reviews is variable from year to year 
[Figure 1(b)]. The world map [Figure 1(c)] reveals 
that the USA and South Korea, respectively, pub-
lished 32.3% and 24.0% of the citations. 
Plasma production
Two methods of plasma production were found 
(Figure 2), although the majority of studies used 
the plasma jet rather than the DBD (72.1% and 
27.8%, respectively). One study did not specify 
the type of plasma production.27 Helium alone 
was the most-used carrier gas (35.8%), followed 
by air (26.3%) and argon (22.1%) (Table 1).
Three studies did not specify the gas used to pro-
duce the plasma.27–29 The use of argon seems to 
be on the rise since 2015, while the use of helium 
remains stable since 2014 (Figure 3).
Figure 1. Geographical distribution and type of the 
included studies.
(a) Cumulative histogram of the evolution over years of the 
number of articles and reviews; (b) proportion of articles 
and reviews by year; only original articles and reviews were 
included (n = 220); (c) geographical distribution of the 
included studies; each author’s nationality was recorded; 
consequently, a study may be related to several countries.
Therapeutic Advances in Medical Oncology 10
4 journals.sagepub.com/home/tam
Plasma application
Figure S2 reveals that most of the studies were 
conducted in vitro (180, 94.7%). The propor-
tion of studies with in vivo results remained low 
(27, 14.2%). Few clinical trials (3, 1.6%) have 
been found3,30,31 and two more clinical trials are 
ongoing.32,33 Figure S3 highlights the predomi-
nant use of direct plasma treatments (160, 
84.2%) rather than indirect treatments (49, 
25.7%). However, in recent years, the number 
of studies using an indirect plasma treatment 
has increased, importantly (Figure S3).
Type of neoplasms
The various cancers studied are presented in Table 2. 
The most commonly reported human cancers (166, 
87.4% of total studies) were brain cancer (31, 
16.3%), followed by lung cancer (23, 12.1%) and 
blood cancer (23, 12.1%). Murine cancer cell lines 
are less studied (29, 15.3% of total studies) and are 
represented mainly by melanomas (17, 9.0%).
The temporal analysis of the type of cancers 
derived from either human or murine cell lines 
are presented in Figure 4(a) and 4(b), respec-
tively. The murine cancer cell line (29, 15.3% of 
the total studies) is derived mainly from mela-
noma, and its use significantly increased from 
2009. Between 2011 and 2015, six other murine 
cancer cell lines began to be used. Before 2008, 
only cells from breast, melanoma and hepatocel-
lular cancers were found in human cell line stud-
ies. The year 2009 marked the beginning of the 
use of a wide range of cancer cell lines.
Discussion
This systematic review highlights the multiplicity 
of production methods and clinical applications 
of CAP in the field of oncology. Plasma jet is the 
predominant discharge device used for plasma 
production. Direct CAP treatment is the most 
represented, but indirect treatment appears to be 
increasing in recent years.
In 2012, the World Health Organization esti-
mated the emergence of more than 14 million new 
cases of cancer in the world.34 The search for new, 
complementary, less-invasive anticancer treat-
ments with fewer side effects is therefore in rapid 
expansion. CAP induces apoptosis of cancer cells2 
and therefore represents a promising treatment.
One of its main advantages compared with conven-
tional therapies is the potential of selectivity toward 
cancer cells. 5,16,17,19,35–38 Several hypotheses can be 
put forward to explain this phenomenon. First, an 
additional oxidative stress may exceed the cell sur-
vival limit more easily in cancer cells.16,38 Second, 
Figure 2. Evolution of the number of studies dealing with dielectric barrier discharge or plasma jet over time.
Only nonreview articles were included (n = 190); studies could be considered in multiple categories.
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cancer cells exhibit a higher number of aquaporin 
on their membranes.16 These aquaporins are 
responsible for a more important flow of RONS in 
cancer cells. Finally, the diffusion of RONS has 
been associated with the cholesterol composition of 
the cell membrane. Peroxidation of the membrane 
lipids results in the formation of pores and increases 
diffusion of the reactive species. The membrane of 
cancer cells contains less cholesterol than the mem-
brane of healthy cells. A lower cholesterol fraction 
results in cells less resistant to peroxidation, with 
subsequent increased diffusion of reactive species 
and oxidative stress.17
This selectivity is an essential parameter in the era 
of targeted therapies, since it is well known that 
localized treatments also reduce systemic delete-
rious side effects. The treatment of tumors and in 
particular, solid tumors, by anticancer drugs faces 
three important obstacles: treatment specificity, 
cancer cell resistance and finally, treatment pen-
etration. Because of its physical and chemical 
properties, CAP is a multimodal therapeutic tool 
that could offer an answer to each of these issues. 
CAP seems to have an effect on cancer cells resist-
ant to current treatments. The mechanisms 
involved seem to depend, inter alia, on p53, 
NF-κB, JNK or caspase pathways.39–42 The effects 
of electrical fields on cancer cells have been stud-
ied in vitro, in vivo and on patients. The electrical 
field causes apoptosis of cancer cells, inhibits 
tumor growth and improves the survival rate of 
patients with glioblastoma.43 Moreover, Janigro 
and colleagues44 demonstrated that the treatment 
of neoplasms by coupling chemotherapy and 
electric stimulation improved the therapeutic effi-
ciency, allowing dose reduction of chemotherapy 
drugs by inhibiting multidrug resistance pumps 
(MDR pumps). Vijayarangan and colleagues45 
concluded that the increased delivery efficiency of 
Table 1. Gas used in nonreview articles (n = 190).
Helium Air Argon Helium + 
oxygen
Nitrogen Argon + 
oxygen
Nitrogen 
+ oxygen
Argon + 
nitrogen
Helium + 
oxygen + 
nitrogen
Neon 
argon
Studies, n 68 50 42 21 12 6 2 2 1 1
Proportion 
of studies
35.8% 26.3% 22.1% 11.0% 6.3% 3.2% 1.0% 1.0 0.5% 0.5%
Studies could be considered in several categories.
Figure 3. Yearly distribution of the articles according to the type of carrier gas.
Only nonreview articles were included (n = 190), a study could be considered in multiple categories.
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the molecule was related to the membrane per-
meability resulting from the combined action of 
the RONS and the electric field. The delay 
between each pulse of the electric field plays a key 
role in the permeability. Plasma-induced chemi-
cal species and electric fields make CAP an inter-
esting tool for optimizing drug delivery. 
Endocytosis has also been observed in relation to 
RONS and enhances drug intake.45
Two discharge sources stand out today with 
regard the direct application of CAP at the clini-
cal level: plasma jets and floating-electrode DBD 
(FE-DBD).2,46 The use of a plasma jet allows the 
propagation of plasma in small capillaries. 
Moreover, the use of a carrier gas makes it 
possible to modulate the plasma composition.4 
The prospects of clinical application are in target-
ing the deep organs. The development of a device 
called the plasma gun (which is a plasma jet) 
allows application of the plasma plume up to 1.5 
m from the source.6 Such a system allows the 
application of CAP under endoscopy and falls 
within a context of less-invasive surgery. CAP 
could be considered after tumor resection in 
order to treat the tumor microenvironment and 
the wound margins. On the other hand, when 
using an FE-DBD, the second electrode is not the 
ground, but human tissue or organ. This 
discharge device generates plasma in the air 
and imposes a maximum distance of 3 mm 
between the two electrodes. FE-DBD has also 
Table 2. Cancer and tumor cell lines studied in nonreview articles (n = 190).
Cancer type Human cancer cells, n 
(%)
Murine cancer 
cells, n (%)
Noncancer cells*
Brain 31 (16.3%) 1 (0.5%) –
Lung 23 (12.1%) 3 (1.6%) –
Blood 23 (12.1%) 2 (1.0%) –
Cervical 22 (11.6%) – –
Melanoma 21 (11.0%) 17 (9.0%) –
Breast 19 (10.0%) 2 (1.0%) –
Colorectal 16 (8.4%) 1 (0.5%) –
Head and neck 13 (6.9%) 1 (0.5%) –
Hepatocellular 9 (4.7%) – –
Prostate 8 (4.2%) – –
Ovarian 8 (4.2%) – –
Osteosarcoma 6 (3.2%) – –
Pancreatic 5 (2.6%) 2 (1.0%) –
Bladder 4 (2.1%) – –
Gastric 3 (1.6%) – –
Thyroid 3 (1.6%) – –
Uterine 2 (1.0%) – –
Epidermal 1 (0.5%) – –
Total 166 (87.4%) 29 (15.3%) 7 (3.7%)
A study could be considered in several categories.
*Only studies that target other than cancer cell lines have been accounted for (e.g. plasmid DNA, immortalized cells).
A Dubuc, P Monsarrat et al.
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demonstrated its anticancer properties in vitro 
and in vivo.46,47 However, no study has examined 
the potential superiority of one system over the 
other. Also, the impact of the electric field in the 
use of FE-DBD should be evaluated.
Direct or indirect application does not result in a 
significant difference in plasma effects on cancer 
cells.48,49 A current limit of direct application is 
the depth of plasma delivery. An in vivo study50 
has shown that CAP could induce apoptosis only 
Figure 4. Cumulative histogram of the evolution over the years of the number of articles according to the type 
of cancer studied.
(a) Human cancers; (b) murine cancers. Only nonreview articles were included (n = 190); studies could be considered in 
multiple categories.
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through the top cell layers, showing a depth of 
effective tissue penetration up to 60 μm. However, 
tissue models have shown that the penetration of 
RONS from plasma can reach to a single millim-
eter’s depth.51 Both types of treatment decrease 
cell viability.52 The ultimate objective is to be able 
to bring the benefits of CAP toward the treatment 
of patients. Indirect treatments’ cytotoxic effects 
depend on the medium and the delay between 
exposure and medium change.53 An indirect 
treatment allows the injection of PAM, for 
instance, to treat more superficial tumors (skin, 
oral cavity) by direct approach. Moreover, PAM 
may be stored at −80°C without losing its anti-
cancer effects.54 The study of the most stable and 
effective PAM, opens the way for new pharma-
ceutical products. It is therefore necessary to vali-
date the most reliable therapy for each clinical 
situation, in terms of efficiency and ergonomics.
We showed that helium alone was the most-used 
carrier gas for plasma and that gas mixtures were 
rarely used. The choice of gas is determinant for the 
plasma composition and the concentration of 
RONS. According to Kim and colleagues,55 the rate 
of apoptosis of human breast cancer cells was greater 
with helium, and increased if oxygen was added. 
The amount of ROS increased using helium com-
pared with argon or nitrogen.56 The addition of oxy-
gen to a flow of helium was responsible for a higher 
production of ROS.57 It is not clear which kind of 
CAP is more efficient in anticancer application, and 
more studies are needed to determine the more effi-
cient type of plasma for each type of cancer.
Many cancers may benefit from the use of CAP 
treatments. The most tested cell lines are derived 
from brain tumors. Brain and central nervous sys-
tem cancers account for about 1.8% of new can-
cers and their incidence and mortality rates are 
higher in developed regions (Europe, North 
America, Australia/New Zealand).34 The predomi-
nant use of glioblastoma cell lines shown in this 
study may be related to the aggressive nature of 
this malignant primary brain tumor, whose prog-
nosis is not superior to 1 year with a very limited 
long-term survival. This cancer is also highly resist-
ant to chemotherapy, radiotherapy and surgery.58 
Treatment with CAP could become an effective 
alternative and complementary therapy on these 
cancers. Another predominant field of study is 
melanoma, the most aggressive skin cancer. Its 
prevalence is high, representing 1.6% of the new 
cancers34 and its median overall survival rate is less 
than 2 years. Murine melanoma cancer cell lines 
and human melanoma cancer cell lines represented 
8.6% and 12% of the studies, respectively. 
Melanoma, like brain cancers, is often resistant to 
acute treatment modalities.52 Furthermore, due to 
the anatomical position of the melanoma, a treat-
ment with CAP can be conceived directly or indi-
rectly. Both approaches have shown their efficiency 
in reducing the viability of melanoma cells. 
However, some melanoma cancer lines are less 
sensitive to PAM than to direct treatments.52
Twenty-seven in vivo studies have been identified 
and concluded that there was a significant reduc-
tion in tumor size and an increase in survival rate. 
In vivo interventions were mostly performed on 
subcutaneous tumor xenografts in mice. Another 
study based on the use of a tumor chorioallantoic 
model was conducted.50 Although the results cor-
roborate the in vitro studies, the development of 
models closer to clinical situations is necessary. 
Taking into account the tumor microenviron-
ment is essential and can also be a target of anti-
cancer treatments.59
Tumors are able to evade surveillance of the 
immune system through immunosuppressive 
strategies. The emerging concept of immunother-
apy and immunogenic cell death is to restore or 
rise immunogenicity of tumor cells by exposing 
new antigens.60 Following severe stress, cells 
exhibit damage-associated molecular patterns. 
ROS produced with CAP could elicit immuno-
genic cell death. Furthermore, CAP stimulates the 
recruitment of macrophages and cytotoxic T 
cells.61 Mizuno and colleagues62 suggest that CAP 
may promote adaptive immunity in vivo against 
melanoma cells.
The interest of the plasma is thus triple: local 
induction of an immunogenic cell death, induc-
tion of a systemic response against cancerous cells 
and the induction of an immune memory.63
Finally, only three clinical trials or follow ups 
have been identified. Two of them studied the 
application of CAP on patients with head and 
neck cancers as a palliative treatment or 
before tumor resection. Such a therapeutic choice 
can be explained by the ability of CAP to decon-
taminate,64,65 treat severely infected wounds or 
ulcerations66,67 and induce apoptosis in head and 
neck cancer cell lines.19,68–72 In a recent clinical 
follow up, Metelmann and colleagues73 investi-
gated the effect of CAP on the surface of head 
and neck squamous cell carcinoma tumors. The 
A Dubuc, P Monsarrat et al.
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results have shown an improvement in the quality 
of life of the patients (reduction in odor and anal-
gesic use), tumor reduction and significant 
improvement in tumor decontamination.
In addition, an ongoing clinical trial32 is assessing 
the effect of CAP on the reduction of lymphocele 
following pelvic lymph node dissection during 
robot-assisted radical prostatectomy. Finally, 
another ongoing clinical trial33 is in recruitment 
phase to study the effect of CAP on human cervi-
cal intraepithelial neoplasia, once again showing 
its potential use in oncology.
The increased interest in the use of CAP for can-
cer treatment by the medical community is closely 
related to the need for new therapies. One of the 
future directions in the field of anticancer poten-
tial of CAP may be the action on dysplastic cells 
in particularly extensive lesions in critical areas 
where surgery would be impossible or too inva-
sive. Interestingly, no resistance to CAPs has 
been reported to date.
Conclusion
This study highlights the multiplicity of means of 
production and potential clinical applications of 
CAP in the field of oncology. Its anticancer 
action is mainly mediated by the production of 
reactive species. Among the different promising 
biological effects, plasma can induce apoptosis of 
cancer cells resistant to conventional chemother-
apy and may be used in combination with cur-
rent treatments to obtain a synergetic and 
complementary action. No resistance to CAPs 
have been reported to date. The clinical use of 
this innovative therapy requires the development 
of standardized reliable protocols in order to 
compare the results between future clinical trials. 
More studies are also required to determine the 
more efficient type of plasma for each type of 
cancer. To obtain comparative results, standard-
ized measures of the effectiveness of the different 
systems are necessary. While plasma jets and 
FE-DBDs find their indication in direct 
approaches, DBD opens the way for the develop-
ment of new pharmaceutical products that can 
be generated on an industrial scale.
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